BACKGROUND: Chemotherapy has not been reported to have a significant impact on survival for patients with metastatic melanoma. Bortezomib was shown to have additive/synergistic effects with several chemotherapeutic agents, including paclitaxel and platinum. A phase 1 trial of this 3-drug combination reported that 6 of 28 patients treated with bortezomib followed by paclitaxel and carboplatin achieved a partial response (including 2 of 5 patients with metastatic melanoma). METHODS: A 2-stage phase 2 clinical trial was conducted to assess the antitumor activity of this 3-agent combination in patients with metastatic melanoma who had received at most 1 prior chemotherapy for metastatic disease. Treatment included bortezomib at a dose of 1.3 mg/m2 intravenously on Days 1, 4, and 8; paclitaxel at a dose of 175 mg/m2; and carboplatin at an area under the concentration (AUC) of 6 on Day 2 of a 21-day cycle. The primary endpoint of this trial was tumor response rate (TRR). RESULTS: Seventeen eligible patients were enrolled. A median of 4 cycles were administered (range, 1-7 cycles). Three patients discontinued treatment due to persistent grade 4 (based on National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]) neutropenia with grade 3 leukopenia (2 patients) or grade 4 pulmonary embolism (1 patient). Grade>or=3 toxicities included neutropenia (71%), leukopenia (41%), thrombocytopenia (29%), and arthralgia (12%). Two partial responses were observed (TRR, 11.8%). Four patients had stable disease at >12 weeks. The median progression-free survival was 3.2 months, and the median overall survival was 7.0 months. CONCLUSIONS: Due to insufficient clinical efficacy, this trial did not proceed to second-stage accrual. The combination of paclitaxel, carboplatin, and bortezomib demonstrated limited clinical benefit and was associated with significant toxicity. Copyright (c) 2010 American Cancer Society.
BACKGROUND: Chemotherapy has not been reported to have a significant impact on survival for patients with metastatic melanoma. Bortezomib was shown to have additive/synergistic effects with several chemotherapeutic agents, including paclitaxel and platinum. A phase 1 trial of this 3-drug combination reported that 6 of 28 patients treated with bortezomib followed by paclitaxel and carboplatin achieved a partial response (including 2 of 5 patients with metastatic melanoma). METHODS: A 2-stage phase 2 clinical trial was conducted to assess the antitumor activity of this 3-agent combination in patients with metastatic melanoma who had received at most 1 prior chemotherapy for metastatic disease. Treatment included bortezomib at a dose of 1.3 mg/m2 intravenously on Days 1, 4, and 8; paclitaxel at a dose of 175 mg/m2; and carboplatin at an area under the concentration (AUC) of 6 on Day 2 of a 21-day cycle. The primary endpoint of this trial was tumor response rate (TRR). RESULTS: Seventeen eligible patients were enrolled. A median of 4 cycles were administered (range, 1-7 cycles). Three patients discontinued treatment due to persistent grade 4 (based on National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]) neutropenia with grade 3 leukopenia (2 patients) or grade 4 pulmonary embolism (1 patient). Grade>or=3 toxicities included neutropenia (71%), leukopenia (41%), thrombocytopenia (29%), and arthralgia (12%). Two partial responses were observed (TRR, 11.8%). Four patients had stable disease at >12 weeks. The median progression-free survival was 3.2 months, and the median overall survival was 7.0 months. CONCLUSIONS: Due to insufficient clinical efficacy, this trial did not proceed to second-stage accrual. The combination of paclitaxel, carboplatin, and bortezomib demonstrated limited clinical benefit and was associated with significant toxicity. Copyright (c) 2010 American Cancer Society.
Authors: M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Svetomir N Markovic; Susan M Geyer; Fitzroy Dawkins; William Sharfman; Mark Albertini; William Maples; Paula M Fracasso; Tom Fitch; Patricia Lorusso; Alex A Adjei; Charles Erlichman Journal: Cancer Date: 2005-06-15 Impact factor: 6.860
Authors: P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: F Stephen Hodi; Robert J Soiffer; Jeffrey Clark; Dianne M Finkelstein; Frank G Haluska Journal: Am J Clin Oncol Date: 2002-06 Impact factor: 2.339
Authors: Deepa Jagtap; Carol A Rosenberg; Lisa W Martin; Mary Pettinger; Janardan Khandekar; Dorothy Lane; Ira Ockene; Michael S Simon Journal: Cancer Date: 2012-03-20 Impact factor: 6.860
Authors: Aminah Jatoi; Jacob B Allred; Vera J Suman; Edward T Creagan; Gary A Croghan; Thomas Amatruda; Svetomir N Markovic Journal: J Geriatr Oncol Date: 2012-05-07 Impact factor: 3.599
Authors: Janice M Mehnert; Antoinette R Tan; Rebecca Moss; Elizabeth Poplin; Mark N Stein; Mika Sovak; Kelly Levinson; Hongxia Lin; Michael Kane; Murugesan Gounder; Yong Lin; Weichung Joe Shih; Eileen White; Eric H Rubin; Vassiliki Karantza Journal: Mol Cancer Ther Date: 2011-06-16 Impact factor: 6.261
Authors: Joseph Markowitz; Eric A Luedke; Valerie P Grignol; Erinn M Hade; Bonnie K Paul; Bethany L Mundy-Bosse; Taylor R Brooks; Thao-Vi Dao; Sri V Kondalasula; Gregory B Lesinski; Thomas Olencki; Kari L Kendra; William E Carson Journal: J Immunother Date: 2014-01 Impact factor: 4.456